Recent advances in the pathogenesis and management of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are presented. These diseases are both diagnosable and treatable. The role of Campylobacter infection preceding GBS and the use of intravenous immunoglobulin to treat CIDP are discussed.